skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Rhabdomyosarcoma Arising in a Previously Irradiated Field: An Analysis of 43 Patients

Abstract

Patients with soft tissue sarcomas that arise from previously irradiated fields have traditionally been reported to have a poor prognosis. In this report, we examined the characteristics and outcomes of patients who developed a rhabdomyosarcoma in a previously irradiated field (RMS-RIF); we hypothesize that these patients should have a better outcome compared to other postradiation soft tissue sarcomas as these tumors are chemosensitive and radiosensitive. A PubMed search of the literature from 1961-2010 yielded 33 studies with data for patients with RMS-RIF. The study included 43 patients with a median age of 6.5 years at the time of radiation therapy (RT) for the initial tumor. The median RT dose was 48 Gy. The median latency period, the time from RT to development of RMS-RIF, was 8 years. The 3-year overall survival for RMS-RIF was 42%. The 3-year overall survival was 66% for patients receiving chemotherapy and local treatment (surgery and/or RT) compared to 29% for those who had systemic treatment only or local treatment only (P=.049). Other factors associated with increased 3-year overall survival included retinoblastoma initial diagnosis (P<.001), age ≤18 years at diagnosis of RMS-RIF (P=.003), favorable site (P=.008), and stage 1 disease (P=.002). Age at time of RMS-RIF,more » retinoblastoma initial tumor, favorable site, stage 1 disease, and use of both systemic and local treatment were found to be favorable prognostic factors for 3-year overall survival.« less

Authors:
 [1];  [2]
  1. Department of Radiation Oncology, Baylor College of Medicine, Houston, Texas (United States)
  2. Department of Radiation Oncology, The Methodist Hospital and Methodist Hospital Research Institute, Houston, Texas (United States)
Publication Date:
OSTI Identifier:
22224347
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 85; Journal Issue: 3; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANIMAL TISSUES; CHEMOTHERAPY; DIAGNOSIS; IRRADIATION; LATENCY PERIOD; PATIENTS; RADIATION DOSES; RADIOTHERAPY; SARCOMAS; SURGERY

Citation Formats

Dang, Nguyen D., Teh, Bin S., and Paulino, Arnold C., E-mail: apaulino@tmhs.org. Rhabdomyosarcoma Arising in a Previously Irradiated Field: An Analysis of 43 Patients. United States: N. p., 2013. Web. doi:10.1016/J.IJROBP.2012.06.011.
Dang, Nguyen D., Teh, Bin S., & Paulino, Arnold C., E-mail: apaulino@tmhs.org. Rhabdomyosarcoma Arising in a Previously Irradiated Field: An Analysis of 43 Patients. United States. https://doi.org/10.1016/J.IJROBP.2012.06.011
Dang, Nguyen D., Teh, Bin S., and Paulino, Arnold C., E-mail: apaulino@tmhs.org. 2013. "Rhabdomyosarcoma Arising in a Previously Irradiated Field: An Analysis of 43 Patients". United States. https://doi.org/10.1016/J.IJROBP.2012.06.011.
@article{osti_22224347,
title = {Rhabdomyosarcoma Arising in a Previously Irradiated Field: An Analysis of 43 Patients},
author = {Dang, Nguyen D. and Teh, Bin S. and Paulino, Arnold C., E-mail: apaulino@tmhs.org},
abstractNote = {Patients with soft tissue sarcomas that arise from previously irradiated fields have traditionally been reported to have a poor prognosis. In this report, we examined the characteristics and outcomes of patients who developed a rhabdomyosarcoma in a previously irradiated field (RMS-RIF); we hypothesize that these patients should have a better outcome compared to other postradiation soft tissue sarcomas as these tumors are chemosensitive and radiosensitive. A PubMed search of the literature from 1961-2010 yielded 33 studies with data for patients with RMS-RIF. The study included 43 patients with a median age of 6.5 years at the time of radiation therapy (RT) for the initial tumor. The median RT dose was 48 Gy. The median latency period, the time from RT to development of RMS-RIF, was 8 years. The 3-year overall survival for RMS-RIF was 42%. The 3-year overall survival was 66% for patients receiving chemotherapy and local treatment (surgery and/or RT) compared to 29% for those who had systemic treatment only or local treatment only (P=.049). Other factors associated with increased 3-year overall survival included retinoblastoma initial diagnosis (P<.001), age ≤18 years at diagnosis of RMS-RIF (P=.003), favorable site (P=.008), and stage 1 disease (P=.002). Age at time of RMS-RIF, retinoblastoma initial tumor, favorable site, stage 1 disease, and use of both systemic and local treatment were found to be favorable prognostic factors for 3-year overall survival.},
doi = {10.1016/J.IJROBP.2012.06.011},
url = {https://www.osti.gov/biblio/22224347}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 3,
volume = 85,
place = {United States},
year = {Fri Mar 01 00:00:00 EST 2013},
month = {Fri Mar 01 00:00:00 EST 2013}
}